Quick Answer
Aquestive Therapeutics, Inc. reported Operating Income Loss of -$71.05 million for the year ending 2025.
- Aquestive Therapeutics, Inc. showed a decrease of -130.9% in Operating Income Loss from 2024 to 2025.
- This data is from Aquestive Therapeutics, Inc.'s annual report (Form 10-K), filed with the SEC on March 4, 2026.
- XBRL data for this metric is available from 2017 to 2025 (9 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q2 2017: -$4.06 million | Q3 2017: $10.42 million | Q1 2018: $5.31 million | Q2 2018: -$32.71 million | Q3 2018: -$9.21 million | Q1 2019: -$13.07 million | Q2 2019: -$18.69 million | Q3 2019: -$11.00 million | Q1 2020: -$13.86 million | Q2 2020: $395.0 thousand | Q3 2020: -$13.78 million | Q1 2021: -$8.53 million | Q2 2021: -$6.52 million | Q3 2021: -$7.97 million | Q1 2022: -$9.74 million | Q2 2022: -$12.76 million | Q3 2022: -$8.85 million | Q1 2023: -$4.61 million | Q2 2023: -$4.21 million | Q3 2023: -$2.38 million | Q1 2024: -$8.96 million | Q2 2024: $55.0 thousand | Q3 2024: -$8.29 million | Q1 2025: -$19.37 million | Q2 2025: -$11.37 million | Q3 2025: -$11.48 million.
- Over the full 9 years of available data (2017 to 2025), Aquestive Therapeutics, Inc.'s Operating Income Loss has declined by 62,777.0%.
- Historical annual values: Fiscal year 2025: -$71.05 million | Fiscal year 2024: -$30.77 million | Fiscal year 2023: -$15.10 million | Fiscal year 2022: -$42.07 million | Fiscal year 2021: -$34.68 million | Fiscal year 2020: -$42.89 million | Fiscal year 2019: -$52.67 million | Fiscal year 2018: -$48.93 million | Fiscal year 2017: -$113.0 thousand.
- Data sourced from SEC EDGAR public filings as of August 9, 2026.
Last verified: